In the present study, AYZ effectively alleviated DNCB-induced AD-Like symptoms and reduced AD-induced inflammation by suppressing the activation of the NLRP3 inflammasome and the MAPKs/NF-kB signaling pathway. The gene discussed is NLRP3; the disease is Alzheimer disease.